NO20083288L - Konjungat for behandling av tumorer - Google Patents

Konjungat for behandling av tumorer

Info

Publication number
NO20083288L
NO20083288L NO20083288A NO20083288A NO20083288L NO 20083288 L NO20083288 L NO 20083288L NO 20083288 A NO20083288 A NO 20083288A NO 20083288 A NO20083288 A NO 20083288A NO 20083288 L NO20083288 L NO 20083288L
Authority
NO
Norway
Prior art keywords
tumors
treatment
antitumor
conjugate
specific
Prior art date
Application number
NO20083288A
Other languages
English (en)
Inventor
Yongzhang Luo
Qingxin Lei
Guodong Chang
Hao Zhou
Original Assignee
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protgen Ltd filed Critical Protgen Ltd
Publication of NO20083288L publication Critical patent/NO20083288L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives et antitumorprotein koblet med en spesifikt modifiserende reagens ved et spesifikt sete for å overkomme iboende mangler til antitumorproteinet, så som høy antigenisitet og kort halveringstid, og for å omgå manglene som er resultatet av ikke-spesifikt modifiserende metoder, så som inkonsistente modifiserte seter, inhomogene bestanddeler, signifikant redusert aktivitet og kvalitet som er vans.kelig åregulere i produktene, og for til slutt å gjøre det mulig ved behandling av tumorer og produksjon av antitumormedikamenter.
NO20083288A 2006-01-20 2008-07-24 Konjungat for behandling av tumorer NO20083288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610011246A CN101002945B (zh) 2006-01-20 2006-01-20 一种用于肿瘤治疗的新型复合物
PCT/CN2007/000203 WO2007082482A1 (fr) 2006-01-20 2007-01-19 Nouveau composé de traitement de tumeur

Publications (1)

Publication Number Publication Date
NO20083288L true NO20083288L (no) 2008-10-20

Family

ID=38287272

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083288A NO20083288L (no) 2006-01-20 2008-07-24 Konjungat for behandling av tumorer

Country Status (8)

Country Link
US (1) US20100303893A1 (no)
EP (1) EP1987838B1 (no)
JP (1) JP2009523433A (no)
CN (1) CN101002945B (no)
AU (1) AU2007207267B2 (no)
CA (1) CA2637687C (no)
NO (1) NO20083288L (no)
WO (1) WO2007082482A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413694A4 (en) * 2009-04-03 2014-02-26 Univ Toledo PEG-ALBUMIN COMPOSITION HAVING AT LEAST ONE PROTECTED THIOL REGION AS A PLATFORM FOR MEDICAMENTS
CN110124051B (zh) * 2011-06-06 2022-10-21 星法马私人有限公司 大分子
TW201611843A (en) * 2012-04-04 2016-04-01 Polaris Group Methods of treatment with arginine deiminase
US9506897B2 (en) * 2012-11-16 2016-11-29 Agilent Technologies, Inc. Methods and compositions for improved ion-exchange chromatography
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
ES2805360T3 (es) 2013-03-15 2021-02-11 Tdw Group Arginina desiminasa con reactividad cruzada reducida hacia anticuerpos para ADI - PEG 20 para el tratamiento del cáncer
KR102353046B1 (ko) 2014-03-18 2022-01-19 티디더블유 그룹 조작된 키메라성 페길화된 ａｄｉ 및 사용 방법
CN104031261B (zh) * 2014-06-20 2017-10-27 电子科技大学 温敏性共聚物及其水凝胶体系
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TWI775160B (zh) * 2014-09-16 2022-08-21 開曼群島商瑞華藥業集團 用於治療癌症之與adi-peg 20抗體具有降低之交叉反應性的精胺酸脫亞胺酶
CN105801870B (zh) * 2016-04-08 2018-08-21 北京华熙海御科技有限公司 一种聚唾液酸-透明质酸复合凝胶的制备方法及所得产品和应用
CN108265068B (zh) * 2016-12-31 2021-06-15 江苏众红生物工程创药研究院有限公司 重组精氨酸脱亚胺酶及其产业化制备方法和应用
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911929A (en) 1986-08-29 1990-03-27 The United States Of America As Represented By The Secretary Of The Navy Blood substitute comprising liposome-encapsulated hemoglobin
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
JP2900279B2 (ja) 1989-08-02 1999-06-02 株式会社ジャパンエナジー 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤
JP3209338B2 (ja) * 1990-09-10 2001-09-17 株式会社ジャパンエナジー ポリエチレングリコール修飾アルギニンデイミナーゼおよびその製造法
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
ATE245444T1 (de) 1998-02-09 2003-08-15 Enzon Pharmaceuticals Inc Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
US6689762B1 (en) 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
EP1264840B1 (en) 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
CA2430077A1 (en) * 2000-11-28 2002-06-06 Phoenix Pharmacologics, Inc. Modified arginine deiminase
HK1053577A2 (en) * 2002-06-20 2003-10-10 Bio Cancer Treatment Int Ltd Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation
US20060122583A1 (en) * 2002-06-25 2006-06-08 Glucon Inc Method and apparatus for performing myocardial revascularization
EP1599217B1 (en) * 2002-11-18 2014-04-16 Polaris Group Methods for inhibiting viral replication in vivo
WO2004076474A2 (en) 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
CN1536079A (zh) * 2003-04-09 2004-10-13 上海复旦张江生物医药股份有限公司 修饰的精氨酸脱亚氨酶
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
CN100355784C (zh) 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
JP2005245269A (ja) 2004-03-03 2005-09-15 Nipro Corp 血清アルブミン多量体を含む遺伝子組換え型蛋白質
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1311867C (zh) 2004-09-27 2007-04-25 侯新朴 一种用于鼻腔给药的神经生长因子制剂

Also Published As

Publication number Publication date
AU2007207267B2 (en) 2012-06-28
CA2637687A1 (en) 2007-07-26
EP1987838A1 (en) 2008-11-05
EP1987838B1 (en) 2016-01-13
AU2007207267A1 (en) 2007-07-26
WO2007082482B1 (fr) 2007-09-07
CN101002945A (zh) 2007-07-25
US20100303893A1 (en) 2010-12-02
WO2007082482A1 (fr) 2007-07-26
JP2009523433A (ja) 2009-06-25
CN101002945B (zh) 2012-09-05
EP1987838A4 (en) 2010-02-24
CA2637687C (en) 2015-07-14

Similar Documents

Publication Publication Date Title
NO20083288L (no) Konjungat for behandling av tumorer
Heath et al. The biology and rationale of targeting nectin-4 in urothelial carcinoma
MX365235B (es) Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
WO2009126934A3 (en) Detection and tratment of pancreatic, ovarian and other cancers
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
WO2007011606A3 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
NZ701709A (en) Monoclonal antibodies to progastrin and their uses
UA95958C2 (en) Antibody that binds to cd22, immunoconjugates and uses therefor
JP2008530138A5 (no)
AU2007221366A8 (en) Oxyntomodulin derivatives
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
NO20082683L (no) Neuroendokrin tumorbehandling
TW200744568A (en) Epinephrine dosing regimens
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
WO2007062174A3 (en) Devices and methods for high-pressure refolding of proteins
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.
Dantuluri et al. Proteome targets of ubiquitin‐like samp1ylation are associated with sulfur metabolism and oxidative stress in Haloferax volcanii
WO2007115660A3 (de) Verfahren und vorrichtung zur herstellung von stickstoffdünger aus biogenen stoffen
WO2006110496A3 (en) Activation of sodium potassium atpase
WO2006036175A3 (en) Wnt proteins and detection and treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application